42 Percent Of Antidepressant Response Explained By Common Gene Variants
A new study published in Biological Psychiatry now shares progress in identifying genomic predictors of antidepressant response.
Many previous studies have searched for genetic markers that may predict antidepressant response, but have done so despite not knowing the contribution of genetic factors. Dr. Katherine Tansey of Institute of Psychiatry at King's College London and colleagues resolved to answer that question.
"Our study quantified, for the first time, how much is response to antidepressant medication influenced by an individual's genetic make-up," said Tansey.
To perform this work, the researchers estimated the magnitude of the influence of common genetic variants on antidepressant response using a sample of 2,799 antidepressant-treated subjects with major depressive disorder and genome-wide genotyping data.
They found that genetic variants explain 42% of individual differences, and therefore, significantly influence antidepressant response.
"While we know that there are no genetic markers with strong effect, this means that there are many genetic markers involved. While each specific genetic marker may have a small effect, they may add up to make a meaningful prediction," Tansey added.
"We have a very long way to go to identify genetic markers that can usefully guide the treatment of depression. There are two critical challenges to this process," said Dr. John Krystal, Editor of Biological Psychiatry. "First, we need to have genomic markers that strongly predict response or non-response to available treatments. Second, markers for non-response to available treatments also need to predict response to an alternative treatment. Both of these conditions need to be present for markers of non-response to guide personalized treatments of depression."
"Although the Tansey et al. study represents progress, it is clear that we face enormous challenges with regards to both objectives," he added. "For example, it does not yet appear that having a less favorable genomic profile is a sufficiently strong negative predictor of response to justify withholding antidepressant treatment. Similarly, there is lack of clarity as to how to optimally treat patients who might have less favorable genomic profile."
Additional research is certainly required, but scientists hope that one day, results such as these can lead to personalized treatment for depression.
The article is "Contribution of Common Genetic Variants to Antidepressant Response" by Katherine E. Tansey, Michel Guipponi, Xiaolan Hu, Enrico Domenici, Glyn Lewis, Alain Malafosse, Jens R. Wendland, Cathryn M. Lewis, Peter McGuffin, and Rudolf Uher (doi: 10.1016/j.biopsych.2012.10.030). The article appears in Biological Psychiatry, Volume 73, Issue 7 (April 1, 2013), published by Elsevier.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Elsevier. "42 Percent Of Antidepressant Response Explained By Common Gene Variants." Medical News Today. MediLexicon, Intl., 2 Apr. 2013. Web.
27 Feb. 2017. <http://www.medicalnewstoday.com/releases/258404.php>
Elsevier. (2013, April 2). "42 Percent Of Antidepressant Response Explained By Common Gene Variants." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.